bioAffinity Technologies Pivots to CyPath® Lung, Sees 87% Revenue Surge
Event summary
- CyPath® Lung revenue rose 87% YoY in 2025, with unit sales up 99%, as bioAffinity streamlined operations by discontinuing unprofitable pathology services.
- The company expanded its physician network by 67%, with plans to accelerate growth in 2026 through sales force expansion.
- bioAffinity raised $16.9 million in 2025 to fund CyPath® Lung development and commercialization.
- A longitudinal trial for CyPath® Lung began in March 2026, enrolling patients across 17 medical centers.
The big picture
bioAffinity’s strategic pivot to CyPath® Lung reflects a broader industry shift toward noninvasive diagnostics for early-stage lung cancer. The company’s operational streamlining and physician network expansion position it to capitalize on a growing market opportunity, with the number of indeterminate pulmonary nodules in the U.S. projected to rise 62% by 2030. However, its ability to maintain momentum will depend on clinical validation and sustained physician adoption.
What we're watching
- Market Expansion
- Whether bioAffinity can sustain its 100%+ projected unit sales growth for CyPath® Lung in 2026 as it enters new markets.
- Clinical Validation
- How the longitudinal trial results will impact CyPath® Lung’s adoption in federal and commercial markets.
- Pipeline Progress
- The pace at which bioAffinity advances its COPD and asthma diagnostics, leveraging its flow cytometry expertise.
Related topics